tipifarnib has been researched along with Bladder Cancer in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chung, W; Hong, JH; Jeong, BC; Jeong, DE; Jo, A; Joo, KM; Lee, HO; Lee, HW; Lim, JE; Nam, DH; Park, SH; Park, WY | 1 |
| Mardiak, J; Moore, M; Palmer, PA; Perez-Ruixo, JJ; Rosenberg, JE; Sahasrabudhe, D; Seigne, JD; Small, EJ; Vaughn, DJ; von der Maase, H | 1 |
2 trial(s) available for tipifarnib and Bladder Cancer
| Article | Year |
|---|---|
Single-cell RNA sequencing reveals the tumor microenvironment and facilitates strategic choices to circumvent treatment failure in a chemorefractory bladder cancer patient.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Drug Resistance, Neoplasm; Humans; Male; Mice; Middle Aged; Proto-Oncogene Proteins p21(ras); Quinolones; RNA-Seq; Single-Cell Analysis; Transcriptome; Treatment Failure; Tumor Microenvironment; Urinary Bladder Neoplasms | 2020 |
A phase II trial of R115777, an oral farnesyl transferase inhibitor, in patients with advanced urothelial tract transitional cell carcinoma.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Transitional Cell; Diarrhea; Enzyme Inhibitors; Exanthema; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neutropenia; Prospective Studies; Quinolones; Remission Induction; Urinary Bladder Neoplasms; Urologic Neoplasms; Urothelium | 2005 |